1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Bone	_	_	NN	_	_	_	_	_
2	disorders	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	especially	_	_	RB	_	_	_	_	_
5	osteoporosis	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	becoming	_	_	VBG	_	_	_	_	_
9	increasingly	_	_	RB	_	_	_	_	_
10	prevalent	_	_	JJ	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	aging	_	_	JJ	_	_	_	_	_
14	population	_	_	NN	_	_	_	_	_
15	grows	_	_	VBZ	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	bone	_	_	NN	_	_	_	_	_
19	fractures	_	_	NNS	_	_	_	_	_
20	also	_	_	RB	_	_	_	_	_
21	occur	_	_	VBP	_	_	_	_	_
22	frequently	_	_	RB	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Osteoporosis	_	_	NN	_	_	_	_	_
2	contributes	_	_	VBZ	_	_	_	_	_
3	significantly	_	_	RB	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	global	_	_	JJ	_	_	_	_	_
6	healthcare	_	_	NN	_	_	_	_	_
7	costs	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	treatment	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	osteoporosis	_	_	NN	_	_	_	_	_
14	remains	_	_	VBZ	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	great	_	_	JJ	_	_	_	_	_
17	challenge	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	new	_	_	JJ	_	_	_	_	_
4	bone	_	_	NN	_	_	_	_	_
5	anabolic	_	_	JJ	_	_	_	_	_
6	drugs	_	_	NNS	_	_	_	_	_
7	need	_	_	VBP	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	developed	_	_	VBN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	prevention	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	osteoporosis	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Bone	_	_	NN	_	_	_	_	_
2	morphogenetic	_	_	JJ	_	_	_	_	_
3	protein	_	_	NN	_	_	_	_	_
4	2	_	_	CD	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	BMP2	_	_	NN	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	one	_	_	CD	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	most	_	_	RBS	_	_	_	_	_
13	important	_	_	JJ	_	_	_	_	_
14	growth	_	_	NN	_	_	_	_	_
15	factors	_	_	NNS	_	_	_	_	_
16	that	_	_	WDT	_	_	_	_	_
17	induce	_	_	VBP	_	_	_	_	_
18	osteoblast	_	_	NN	_	_	_	_	_
19	differentiation	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	stimulate	_	_	VBP	_	_	_	_	_
22	bone	_	_	NN	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	cartilage	_	_	NN	_	_	_	_	_
25	formation	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	BMP2	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	widely	_	_	RB	_	_	_	_	_
5	used	_	_	VBN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	clinic	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	promote	_	_	VB	_	_	_	_	_
11	bone	_	_	NN	_	_	_	_	_
12	formation	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	therapeutic	_	_	JJ	_	_	_	_	_
5	dose	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	BMP2	_	_	NNP	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	very	_	_	RB	_	_	_	_	_
10	expensive	_	_	JJ	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	there	_	_	EX	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	some	_	_	DT	_	_	_	_	_
16	life-threatening	_	_	JJ	_	_	_	_	_
17	side	_	_	NN	_	_	_	_	_
18	effects	_	_	NNS	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	can	_	_	MD	_	_	_	_	_
21	occur	_	_	VB	_	_	_	_	_
22	with	_	_	IN	_	_	_	_	_
23	larger	_	_	JJR	_	_	_	_	_
24	doses	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Hence	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	necessary	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	find	_	_	VB	_	_	_	_	_
8	additional	_	_	JJ	_	_	_	_	_
9	agents	_	_	NNS	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	methods	_	_	NNS	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	improvement	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	BMP2	_	_	NNP	_	_	_	_	_
17	itself	_	_	PRP	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	intensify	_	_	VB	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	osteogenic	_	_	JJ	_	_	_	_	_
22	effects	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	BMP2	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	combination	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	BMP2	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	small	_	_	JJ	_	_	_	_	_
8	molecules	_	_	NNS	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	promote	_	_	VB	_	_	_	_	_
11	BMP2-mediated	_	_	JJ	_	_	_	_	_
12	osteoblast	_	_	NN	_	_	_	_	_
13	differentiation	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	reduces	_	_	VBZ	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	risk	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	its	_	_	PRP$	_	_	_	_	_
20	side	_	_	NN	_	_	_	_	_
21	effects	_	_	NNS	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	treatment	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	bone	_	_	NN	_	_	_	_	_
27	diseases	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	From	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	clinical	_	_	JJ	_	_	_	_	_
4	perspective	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	small	_	_	JJ	_	_	_	_	_
8	molecules	_	_	NNS	_	_	_	_	_
9	that	_	_	WDT	_	_	_	_	_
10	regulate	_	_	VBP	_	_	_	_	_
11	BMP2	_	_	NNP	_	_	_	_	_
12	activity	_	_	NN	_	_	_	_	_
13	provide	_	_	VBP	_	_	_	_	_
14	powerful	_	_	JJ	_	_	_	_	_
15	tools	_	_	NNS	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	treatment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	osteoporosis	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	fracture	_	_	NN	_	_	_	_	_
23	repair	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Icariin	_	_	NNP	_	_	_	_	_
2	(	_	_	-LRB-	_	_	_	_	_
3	ICA	_	_	NNP	_	_	_	_	_
4	)	_	_	-RRB-	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	chemical	_	_	JJ	_	_	_	_	_
8	structure	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	shown	_	_	VBN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	main	_	_	JJ	_	_	_	_	_
5	active	_	_	JJ	_	_	_	_	_
6	flavonoid	_	_	NN	_	_	_	_	_
7	glucoside	_	_	NN	_	_	_	_	_
8	from	_	_	IN	_	_	_	_	_
9	herbs	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	genus	_	_	NN	_	_	_	_	_
13	Epimedium	_	_	NNP	_	_	_	_	_
14	;	_	_	:	_	_	_	_	_
15	these	_	_	DT	_	_	_	_	_
16	herbs	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	used	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	traditional	_	_	JJ	_	_	_	_	_
21	Chinese	_	_	JJ	_	_	_	_	_
22	medicine	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	have	_	_	VBP	_	_	_	_	_
25	long	_	_	RB	_	_	_	_	_
26	been	_	_	VBN	_	_	_	_	_
27	prescribed	_	_	VBN	_	_	_	_	_
28	for	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	treatment	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	bone	_	_	NN	_	_	_	_	_
33	fractures	_	_	NNS	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	osteoporosis	_	_	NN	_	_	_	_	_
36	as	_	_	IN	_	_	_	_	_
37	a	_	_	DT	_	_	_	_	_
38	bone-protecting	_	_	JJ	_	_	_	_	_
39	agent	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	promoting	_	_	VBG	_	_	_	_	_
5	bone	_	_	NN	_	_	_	_	_
6	regeneration	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	repair	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	ICA	_	_	NNP	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	has	_	_	VBZ	_	_	_	_	_
13	many	_	_	JJ	_	_	_	_	_
14	beneficial	_	_	JJ	_	_	_	_	_
15	pharmacological	_	_	JJ	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	biological	_	_	JJ	_	_	_	_	_
18	activities	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	including	_	_	VBG	_	_	_	_	_
21	neuroprotective	_	_	JJ	_	_	_	_	_
22	effects	_	_	NNS	_	_	_	_	_
23	;	_	_	:	_	_	_	_	_
24	protective	_	_	JJ	_	_	_	_	_
25	effects	_	_	NNS	_	_	_	_	_
26	against	_	_	IN	_	_	_	_	_
27	atherosclerosis	_	_	NN	_	_	_	_	_
28	;	_	_	:	_	_	_	_	_
29	antitumor	_	_	NN	_	_	_	_	_
30	effects	_	_	NNS	_	_	_	_	_
31	;	_	_	:	_	_	_	_	_
32	anti-inflammatory	_	_	JJ	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	antioxidant	_	_	JJ	_	_	_	_	_
35	effects	_	_	NNS	_	_	_	_	_
36	;	_	_	:	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	improved	_	_	VBN	_	_	_	_	_
39	sexual	_	_	JJ	_	_	_	_	_
40	function	_	_	NN	_	_	_	_	_
41	effects	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	animal	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	cell	_	_	NN	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	shown	_	_	VBN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	ICA	_	_	NNP	_	_	_	_	_
12	can	_	_	MD	_	_	_	_	_
13	increase	_	_	VB	_	_	_	_	_
14	osteogenic	_	_	JJ	_	_	_	_	_
15	differentiation	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	reduce	_	_	VB	_	_	_	_	_
18	bone	_	_	NN	_	_	_	_	_
19	loss	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	vivo	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	in	_	_	FW	_	_	_	_	_
24	vitro	_	_	FW	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	extremely	_	_	RB	_	_	_	_	_
3	low	_	_	JJ	_	_	_	_	_
4	cost	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	ICA	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	its	_	_	PRP$	_	_	_	_	_
9	strong	_	_	JJ	_	_	_	_	_
10	bone	_	_	NN	_	_	_	_	_
11	regenerative	_	_	JJ	_	_	_	_	_
12	effects	_	_	NNS	_	_	_	_	_
13	indicate	_	_	VBP	_	_	_	_	_
14	its	_	_	PRP$	_	_	_	_	_
15	potential	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	clinical	_	_	JJ	_	_	_	_	_
18	applications	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	cAMP/PKA/CREB	_	_	NNP	_	_	_	_	_
3	axis	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	vital	_	_	JJ	_	_	_	_	_
7	pathway	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	regulates	_	_	VBZ	_	_	_	_	_
10	osteogenic	_	_	JJ	_	_	_	_	_
11	differentiation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	mineralization	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	reported	_	_	VBN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	PTH	_	_	NNP	_	_	_	_	_
8	affects	_	_	VBZ	_	_	_	_	_
9	osteoblastic	_	_	JJ	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	activating	_	_	VBG	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	cAMP/PKA/CREB	_	_	NNP	_	_	_	_	_
15	axis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	reported	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	pretreatment	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	human	_	_	JJ	_	_	_	_	_
9	mesenchymal	_	_	JJ	_	_	_	_	_
10	stem	_	_	NN	_	_	_	_	_
11	cells	_	_	NNS	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	MSCs	_	_	NNS	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	cAMP	_	_	NN	_	_	_	_	_
17	analogs	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	adenylate	_	_	NN	_	_	_	_	_
20	cyclase	_	_	NN	_	_	_	_	_
21	activators	_	_	NNS	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	phosphodiesterase	_	_	NN	_	_	_	_	_
24	inhibitors	_	_	NNS	_	_	_	_	_
25	can	_	_	MD	_	_	_	_	_
26	enhance	_	_	VB	_	_	_	_	_
27	bone	_	_	NN	_	_	_	_	_
28	formation	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	combined	_	_	VBD	_	_	_	_	_
8	ICA	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	BMP2	_	_	NNP	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	promote	_	_	VB	_	_	_	_	_
13	osteogenesis	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	first	_	_	JJ	_	_	_	_	_
17	time	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	aimed	_	_	VBD	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	determine	_	_	VB	_	_	_	_	_
5	whether	_	_	IN	_	_	_	_	_
6	ICA	_	_	NNP	_	_	_	_	_
7	could	_	_	MD	_	_	_	_	_
8	enhance	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	osteogenic	_	_	JJ	_	_	_	_	_
11	induction	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	BMP2	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	C2C12	_	_	NNP	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	concluded	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	combination	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	ICA	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	BMP2	_	_	NNP	_	_	_	_	_
10	could	_	_	MD	_	_	_	_	_
11	promote	_	_	VB	_	_	_	_	_
12	BMP2-mediated	_	_	JJ	_	_	_	_	_
13	osteoblast	_	_	NN	_	_	_	_	_
14	differentiation	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	dose-dependent	_	_	JJ	_	_	_	_	_
18	manner	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	found	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	ICA	_	_	NNP	_	_	_	_	_
6	stimulates	_	_	VBZ	_	_	_	_	_
7	BMP2-mediated	_	_	JJ	_	_	_	_	_
8	osteogenesis	_	_	NN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	activating	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	cAMP/PKA/CREB	_	_	NN	_	_	_	_	_
13	signaling	_	_	NN	_	_	_	_	_
14	pathway	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	ICA	_	_	NNP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	promising	_	_	JJ	_	_	_	_	_
7	candidate	_	_	NN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	alternative	_	_	NN	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	BMP2	_	_	NNP	_	_	_	_	_
13	or	_	_	CC	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	promoter	_	_	NN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	enhancing	_	_	VBG	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	therapeutic	_	_	JJ	_	_	_	_	_
21	effects	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	BMP2	_	_	NNP	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	combination	_	_	NN	_	_	_	_	_
3	will	_	_	MD	_	_	_	_	_
4	reduce	_	_	VB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	risk	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	side	_	_	NN	_	_	_	_	_
9	effects	_	_	NNS	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	BMP2	_	_	NNP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	bone	_	_	NN	_	_	_	_	_
17	diseases	_	_	NNS	_	_	_	_	_
18	such	_	_	JJ	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	osteoporosis	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_

